Oct 27 2023 This Week in Cardiology

More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback Million Hearts CMS 'Million Hearts' CVD Risk Reduction Model Works https://www.medscape.com/viewarticle/997551 - RCT JAMA - https://jamanetwork.com/journals/jama/fullarticle/2810696 AC in ICH - ENRICH AF Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547 - Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0 - ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1 II. TAVI vs SAVR Low-Risk TAVR Studies: Divergent Long-Term Results https://www.medscape.com/viewarticle/997784 - Partner 3 Main Results - Partner 3 – Five Year - Original EVOLUT -LR https://www.nejm.org/doi/10.1056/NEJMoa1816885 - EVOLUT 3-year https://doi.org/10.1016/j.jacc.2023.02.017 - EVOLUT -LR 4-year https://doi.org/10.1016/j.jacc.2023.09.813 III. Myocardial Viability Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2 https://www.medscape.com/viewarticle/989101 - Revived BCIS – Original paper https://www.nejm.org/doi/10.1056/NEJMoa2206606 - JAMA Cardiology Viability paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2810727 - STICH Viability Paper - https://www.nejm.org/doi/full/10.1056/NEJMoa1100358 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net